EATONTOWN, N.J., Sept. 9 /PRNewswire/ -- Roberts Pharmaceutical
Corporation (Nasdaq: RPCX) announced today that the Company has concluded
private placements representing $115 million in gross proceeds, consisting of
the sale of $105 million Roberts 5% Convertible Preferred Stock and the sale
of $9.9 million Common Stock.  The transactions were managed by Cappello &
Laffer Capital Corp., the exclusive Placement Agent, and were made pursuant to
Regulation D of the Securities Act of 1933.
    The Preferred Stock purchasers, consisting of a group of institutional
investors, have agreed to restrictions on the resale of any Common Stock
acquired on conversion.  Roberts also believes the terms of this transaction
favor long-term holdings of the Preferred Stock prior to conversion.  Based
upon a formula which, over time, adjusts the conversion price to changes in
the market price of the Common Stock, the Preferred Stock is convertible into
Common Stock at a 10% discount and automatically converts into Common Stock on
August 29, 1998.  In line with its listing agreement with Nasdaq, the Company
will hold a meeting of shareholders in the near term to approve the full
number of shares of Common Stock issuable upon conversion of the Preferred
Stock.  Meanwhile, Roberts has put aside a substantial portion of the proceeds
from the offering which would be used to redeem a portion of the Preferred
Stock should approval not be obtained prior to November 28, 1996.  However,
the Company fully expects to obtain shareholder approval.
    The sale of the Common Stock consisted of 600,000 shares sold at $16.65
per share ($9,990,000) to several funds managed by a long-term,
growth-oriented, fund manager.  Net proceeds from this transaction and from
the private placement of the 5% Convertible Preferred Stock will be used to
reduce current debt and for capital expenditures, new drug development, and
potential product acquisitions.
    Commenting on this announcement, Dr. Robert A. Vukovich, President and CEO
of Roberts, said, "We are delighted with the confidence these institutional
investors have shown with regard to this Company's future prospects.  With
this greatly enhanced cash position and with the pending U.S. launch of our
first pipeline drug, ProAmatine(TM), Roberts is well poised for the next and
exciting phase of its long-term growth."  Roberts Pharmaceutical Corporation
is an international pharmaceutical company focusing on the acquisition and
development of late-stage drugs.  Roberts currently markets its products in
seven countries and has operating subsidiaries in the U.S., Canada, and the
United Kingdom.
    This and past news releases by Roberts Pharmaceutical Corporation are
available through PR Newswire's Company News On-Call fax service at
1-800-758-5804, extension 760975 and on the Internet at
http://www.prnewswire.com.
    This release may contain forward-looking statements which reflect
management's current views of future events and operations.  These
forward-looking statements are based on assumptions and external factors,
including assumptions relating to regulatory action and competing products.
Any changes in such assumptions or external factors could produce
significantly different results.

Link to this page: